Cantargia receives Notice of Allowance from USPTO on IL1RAP in solid tumours

The United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Cantargia’s patent application on IL1RAP as target molecule for antibody therapy of several types of solid tumours.

The patent application, with application number 13/979,475 that has now received a Notice of Allowance from the USPTO refers to a method for using IL1RAP as target molecule for treatment of solid tumours. The patent covers treatment of several different forms of solid tumours, including breast cancer, colorectal cancer, lung cancer and malignant melanoma. The issuance of a Notice of Allowance indicates that the USPTO intends to approve the company’s patent application. Certain administrative steps remain before the patent is formally granted.

“Cantargia has passed yet another very important milestone in the development of our CAN04 product candidate”, Göran Forsberg, CEO of Cantargia AB, says. “Once the patent has been formally approved in the US we will have protection in the area of solid tumours in the three largest markets, USA, Europe and Japan.”

For further information, please contact 
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail: goran.forsberg@cantargia.com
Certified Advisor: Sedermera fondkommission